EMPLOYMENT AGREEMENTEmployment Agreement • July 26th, 2019 • KBL Merger Corp. Iv • Blank checks • Delaware
This Employment Agreement (this “Agreement”) is made as of July 23, 2019, between KBL Merger Corp. IV (the “Company”), and Marlene Krauss (“Executive”) (collectively, the Company and Executive are the “Parties”).
FORM OF LOCK-UP AGREEMENTUp Agreement • July 26th, 2019 • KBL Merger Corp. Iv • Blank checks • Delaware
The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that KBL Merger Corp. IV, a Delaware corporation (“KBL”) proposes to enter into a Business Combination Agreement (as the same may be amended from time to time, the “Business Combination Agreement”) with KBL Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of KBL (“Merger Sub”), CannBioRx Life Sciences Corp., a Delaware corporation (the “Company”), Katexco Pharmaceuticals Corp., a British Columbia corporation (“Katexco”), CannBioRex Pharmaceuticals Corp., a British Columbia corporation (“CBR Pharma”), 180 Therapeutics LP, a Delaware limited partnership (“180” and together with Katexco and CBR Pharma, the “Company Subsidiaries”), and Lawrence Pemble, in his capacity as representative of the stockholders of the Company and the Company Subsidiaries which provides, among other things, for the merger of Merger Sub with and into the Company, with the Company continuing as the survi
FORM OF SUPPORT AGREEMENTForm of Support Agreement • July 26th, 2019 • KBL Merger Corp. Iv • Blank checks • Delaware
This SUPPORT AGREEMENT (this “Agreement”), dated as of July 25, 2019, is by and between KBL Merger Corp. IV, a Delaware corporation (“KBL”), and the Person set forth on Schedule A (the “Stockholder”).
BUSINESS COMBINATION AGREEMENT BY AND AMONG KBL MERGER CORP. IV KBL MERGER SUB, INC. CANNBIORX LIFE SCIENCES CORP. KATEXCO PHARMACEUTICALS CORP. CANNBIOREX PHARMACEUTICALS CORP. 180 THERAPEUTICS L.P. AND, in his capacity as the Stockholder...Business Combination Agreement • July 26th, 2019 • KBL Merger Corp. Iv • Blank checks • Delaware
This BUSINESS COMBINATION AGREEMENT (this “Agreement”), dated as of July 25, 2019, is made by and among CannBioRx Life Sciences Corp., a Delaware corporation (the “Company”), Katexco Pharmaceuticals Corp., a British Columbia corporation (“Katexco”), CannBioRex Pharmaceuticals Corp., a British Columbia corporation (“CBR Pharma”), 180 Therapeutics L.P., a Delaware limited partnership (“180” and together with Katexco and CBR Pharma, the “Company Subsidiaries”), KBL Merger Corp. IV, a Delaware corporation (“KBL”), KBL Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Lawrence Pemble, in his capacity as representative of the Company Stockholders and the stockholders of the Company Subsidiaries (the “Stockholder Representative”). The Company, the Company Subsidiaries, KBL, Merger Sub and the Stockholder Representative shall be referred to herein from time to time collectively as the “Parties”. Capitalized terms used but not otherwise defined herein have the meanings set forth in S
